PANACEABIOPanacea Biotec Ltd.

    Panacea Biotec Q2 FY27 Results: Consolidated Net Profit ₹11.91 Crore on Total Income of ₹196 Crore

    • Earnings
    • pharmaceuticals and vaccines
    Two glass laboratory flasks standing in cork rings
    Illustrative image. Photo: Tinux, via Wikimedia Commons (CC0)

    Panacea Biotec (NSE: PANACEABIO) reported consolidated total income of ₹196 crore and net profit of ₹12 crore for the quarter ended 30 Sep 2026; standalone total income was ₹133 crore and net profit ₹11 crore. The company said in a filing on 14 Nov 2026 that its board approved the unaudited results.

    Key highlights

    Consolidated

    Including its subsidiaries

    • Total income: ₹196 crore, up 33.0% YoY and 3.7% lower QoQ
    • Net profit and EPS: ₹12 crore against a loss of ₹14 crore a year earlier; basic EPS ₹1.90
    • Exceptional items: ₹2.77 crore in the quarter; ₹5.51 crore in the half-year
    • Finance costs: ₹1 crore, down 72.0% YoY

    Standalone

    The company on its own, without its subsidiaries

    • Total income: ₹133 crore, up 41.0% YoY and 5.4% lower QoQ
    • Net profit and EPS: ₹11 crore against a loss of ₹16 crore a year earlier; basic EPS ₹1.76
    • Finance costs: ₹6 crore, against ₹6 crore a year earlier

    Summary

    Consolidated ₹ crore
    ParticularsQ2 FY27Q2 FY26YoYQ1 FY27QoQ
    196148+33.0%204-3.7%
    12-14n/a2+441.4%
    EPS, basic (₹)1.90-2.27n/a0.38+400.0%

    Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

    The consolidated figures show a turn from a loss to a profit on a year-earlier basis. Net profit rose to ₹12 crore from a loss of ₹14 crore, while total income rose 33.0% to ₹196 crore. Revenue from operations rose 34.4%, faster than other income, which rose 3.1% to ₹7 crore.

    Other income of ₹6.60 crore is 38.8% of the quarter's profit before tax of ₹16.99 crore. Tax expense of ₹5.08 crore is 29.9% of that pre-tax profit. The filing gives no reason for the change in these figures between quarters.

    Consolidated net profit rose 441.4% from the June quarter, while total income fell 3.7%. The notes record exceptional income of ₹2.77 crore in the quarter and ₹5.51 crore in the half-year, the latter being part of deferred consideration from the sale of domestic pharmaceutical brands of Panacea Biotec Pharma Limited. The balance of ₹4.68 crore is to be recognised in later quarters.

    Standalone ₹ crore
    ParticularsQ2 FY27Q2 FY26YoYQ1 FY27QoQ
    13394+41.0%141-5.4%
    11-16n/a1+673.4%
    EPS, basic (₹)1.76-2.55n/a0.23+665.2%

    Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

    Standalone total income rose 41.0% YoY to ₹133 crore, faster than consolidated total income. Standalone revenue from operations rose 39.5% to ₹127 crore, while other income rose 77.6% to ₹6 crore. Other income of ₹6.41 crore is 45.5% of standalone profit before tax of ₹14.08 crore.

    Finance costs of ₹6.32 crore are 4.5% of standalone total income this quarter, close to the year-earlier level of ₹5.93 crore. Standalone net profit of ₹10.75 crore compares with a loss of ₹15.64 crore a year earlier and ₹1.39 crore in the June quarter.

    The statutory auditor, Suresh Surana & Associates LLP, issued a limited review report on both sets of results and said nothing came to its attention that causes it to believe the statements contain a material misstatement. The auditor's consolidated report says six subsidiaries were included on unaudited results not reviewed by their auditors, and that these are not material to the Group.

    Note 4 says standalone retained earnings are negative to the extent of ₹205.10 crore as on 30 Sep 2026, while the Group's retained earnings are positive. The company says these conditions indicate uncertainty about its ability to continue as a going concern, and that the results are prepared on a going concern basis, citing surplus funds from the March 2022 sale of formulation brands in India and Nepal and higher long-term vaccine orders from institutional customers.

    Inference

    The filing states that the company has a standalone accumulated deficit and that the going concern basis rests on the factors named in note 4. The filing does not state the amount or timing of the long-term vaccine orders it refers to, the reason for the swing from a loss to a profit, or whether a dividend is proposed.

    Filed with BSE on . Reference: Original filing (PDF)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Latest posts